Vericel (VCEL) Earnings Date & Reports

Key Takeaways

• Vericel posted third quarter 2026 total revenue of $85.4 million, up 26% year over year and above the roughly $79.5 million consensus estimate.
• Diluted earnings per share (EPS) came in at $0.27, far surpassing the approximately $0.06 consensus and the $0.10 reported a year earlier.
• MACI revenue reached $67.4 million (up 21%), while Burn Care revenue surged 52% to a record $18 million.
• GAAP net income nearly tripled to $14.2 million, and adjusted EBITDA rose 48% to $25.2 million, a 30% margin.
• Management raised full-year 2026 revenue guidance to $344–$346 million, its third consecutive quarterly increase.
• For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• Discover new trade ideas with Trending AI Robots for additional market insights.

Earnings Context and Why It Matters

Vericel's third quarter 2026 report matters because it tests whether the company's two commercial franchises — MACI (Matrix-induced Autologous Chondrocyte Implantation, a cell therapy for knee cartilage repair) and Burn Care — can sustain the high-growth, margin-expanding trajectory investors have come to expect. Coming off a second quarter in which revenue grew 22%, the third quarter showed growth reaccelerating to 26%, driven by both franchises. With management raising full-year guidance for the third consecutive quarter, this report offers a key read on demand durability, profitability leverage, and the company's progress toward its midterm revenue and profitability targets.

Reported Results

Vericel reported third quarter 2026 total revenue of $85.4 million, a 26% increase from $67.5 million in the prior-year period and significantly above its own guidance range. MACI revenue rose 21% to $67.4 million, marking a sixth consecutive quarter of 20%-plus growth. Burn Care revenue climbed 52% to a record $18 million, with Epicel revenue up 23% to $12.7 million and commercial NexoBrid revenue up 54% to $2.3 million, alongside $3 million in NexoBrid procurement revenue under a BARDA (Biomedical Advanced Research and Development Authority) agreement.

Profitability strengthened sharply. GAAP net income increased 179% to $14.2 million, or $0.27 per diluted share, versus $0.10 a year ago. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose 48% to $25.2 million, with a 30% margin, while gross margin exceeded 73%. The company generated about $18 million in operating cash flow and $16 million in free cash flow, ending the quarter with $236 million in cash and investments and no debt.

Based on the strength, management raised full-year 2026 total revenue guidance to $344–$346 million from $330–$340 million, lifted MACI guidance to $290–$292 million, and raised its adjusted EBITDA margin outlook.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. If you are looking to streamline your research process, the AI Screener may be worth exploring.

Market Reaction and Investor Sentiment

Shares of Vericel rose roughly 13% on November 5, 2026, following the report, reflecting investor enthusiasm for a top- and bottom-line beat paired with a third straight guidance raise. The earnings surprise was especially pronounced on the EPS line, where reported results of $0.27 far exceeded consensus expectations. However, the market also weighed a more nuanced picture: Burn Care revenue was the swing factor in the quarter, and management's fourth-quarter Burn Care framework implied a sequential step back, underscoring the inherently lumpy nature of catastrophic burn volumes. Sentiment heading into the report had turned more cautious, making the beat-and-raise a notable positive catalyst despite lingering questions about the durability of the upside.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will focus on whether Vericel can convert strong leading indicators into sustained growth. MACI biopsies accelerated each quarter in 2026, and October marked the strongest biopsy month since launch — a signal that could support implant volume into 2027. The expanding MACI sales force and rising adoption of MACI Arthro remain central to this story.

Burn Care visibility will be another key factor to watch. Epicel and NexoBrid delivered record quarters, but catastrophic burn volumes are unpredictable, and BARDA procurement revenue is procurement-driven rather than organic demand. Management also indicated that initial 2027 guidance will be set conservatively, anchored near consensus.

Finally, investors should monitor international expansion and new indications. Vericel is targeting a potential MACI launch in the United Kingdom in the second half of 2027 and continues to develop a potential MACI ankle indication. Execution on these catalysts, alongside gross margin progression toward the mid-70s range, will likely shape the next phase of the company's growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations